Half-year report · HY
9776.TEDINET S100X0DA
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥380m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥338m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥390m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥708m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥343m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥389m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥344m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥251m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥464m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥222m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥256m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥226m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥16.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥16.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥716m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥731m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥407m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥584m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥173m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥526m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥398m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥80.4 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.35 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.9% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥43m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥31m |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥153m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥404m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥840m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥505m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥558m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥343m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥590m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥37m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥158m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥352m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥800m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥426m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥545m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Treasury stock | Prior1YearInstant | -947426000 | JPY |
| Treasury stock | InterimInstant | -947426000 | JPY |
| Shareholders equity | Prior1YearInstant | 11046504000 | JPY |
| Shareholders equity | InterimInstant | 11225562000 | JPY |
| Valuation difference on available for sale securities | Prior1YearInstant | 107394000 | JPY |
| Valuation difference on available for sale securities | InterimInstant | 172515000 | JPY |
| Valuation and translation adjustments | Prior1YearInstant | 107394000 | JPY |
| Valuation and translation adjustments | InterimInstant | 172515000 | JPY |
| Non controlling interests | Prior1YearInstant | 240216000 | JPY |
| Non controlling interests | InterimInstant | 245016000 | JPY |
| Net assets | Prior1YearInstant | 11394115000 | JPY |
| Net assets | InterimInstant | 11643094000 | JPY |
| Liabilities and net assets | Prior1YearInstant | 16450937000 | JPY |
| Liabilities and net assets | InterimInstant | 16786417000 | JPY |
| Net sales | Prior1InterimDuration | 9996976000 | JPY |
| Net sales | InterimDuration | 10238068000 | JPY |
| Cost of sales | Prior1InterimDuration | 6963100000 | JPY |
| Cost of sales | InterimDuration | 7128376000 | JPY |
| Gross profit | Prior1InterimDuration | 3033876000 | JPY |
| Gross profit | InterimDuration | 3109691000 | JPY |
| Selling general and administrative expenses | Prior1InterimDuration | 2695992000 | JPY |
| Selling general and administrative expenses | InterimDuration | 2729927000 | JPY |
| Operating income | Prior1InterimDuration | 337884000 | JPY |
| Operating income | InterimDuration | 379764000 | JPY |
| Interest income noi | Prior1InterimDuration | 36000 | JPY |
| Interest income noi | InterimDuration | 1753000 | JPY |
| Dividends income noi | Prior1InterimDuration | 2805000 | JPY |
| Dividends income noi | InterimDuration | 6160000 | JPY |
| Rent income noi | Prior1InterimDuration | 25890000 | JPY |
| Rent income noi | InterimDuration | 70412000 | JPY |
| Insurance fee noi | Prior1InterimDuration | － | JPY |
| Insurance fee noi | InterimDuration | 554000 | JPY |
| Subsidy income noi bounty | Prior1InterimDuration | 264000 | JPY |
| Subsidy income noi bounty | InterimDuration | 3033000 | JPY |
| Other noi | Prior1InterimDuration | 2258000 | JPY |
| Other noi | InterimDuration | 6023000 | JPY |
| Non operating income | Prior1InterimDuration | 31254000 | JPY |
| Non operating income | InterimDuration | 87938000 | JPY |
| Interest expenses noe | Prior1InterimDuration | 3430000 | JPY |
| Interest expenses noe | InterimDuration | 3338000 | JPY |
| Cost of lease revenue noe | Prior1InterimDuration | 21711000 | JPY |
| Cost of lease revenue noe | InterimDuration | 74026000 | JPY |
| Other noe | Prior1InterimDuration | 947000 | JPY |
| Other noe | InterimDuration | 517000 | JPY |
| Non operating expenses | Prior1InterimDuration | 26089000 | JPY |
| Non operating expenses | InterimDuration | 77883000 | JPY |
| Ordinary income | Prior1InterimDuration | 343050000 | JPY |
| Ordinary income | InterimDuration | 389820000 | JPY |
| Gain on sales of noncurrent assets ei | Prior1InterimDuration | 1157000 | JPY |
| Gain on sales of noncurrent assets ei | InterimDuration | 1000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |